Wegovy by Novo Nordisk - obesity drug reshapes a booming market
Published on 07/26/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Wegovy by Novo Nordisk sits in a cool white pen on the pharmacy counter, the teal stripe catching the light as a nurse explains the once-weekly injection to a patient who has tried countless diets. One pen, one click, and a very different approach to weight loss.
Once-weekly GLP-1 for obesity
Wegovy is Novo Nordisk's branded high-dose semaglutide injection approved specifically for chronic weight management in adults with obesity or overweight and at least one weight-related condition. It is given once a week as a subcutaneous injection in pre-filled pens. The active ingredient semaglutide mimics the human GLP-1 hormone, helping reduce appetite, increase satiety and lower food intake.
In the European Union, Wegovy received marketing authorisation from the European Medicines Agency in early 2022 for adults with a body mass index (BMI) of at least 30, or at least 27 with one weight-related comorbidity such as hypertension, type 2 diabetes or dyslipidaemia. In the United States, the Food and Drug Administration approved Wegovy as a chronic weight management therapy in 2021, making it one of the first GLP-1 agonists specifically labelled for obesity rather than diabetes.
Dosing, titration and delivery pens
Patients start Wegovy at a low dose of 0.25 mg once weekly and titrate upwards every four weeks to a maintenance dose of 2.4 mg once weekly, following a structured regimen to minimise gastrointestinal side effects. The medicine is supplied in single-use, pre-filled injection pens with different strengths to match each step of the titration schedule. Each pen is designed for a single weekly dose, stored in the refrigerator and brought to room temperature before injection.
Novo Nordisk markets Wegovy pens with colour-coded labels and clear dose markings, aiming to keep the regimen simple for patients and prescribers. The company emphasises that Wegovy should be used as part of a comprehensive weight management programme, including a reduced-calorie diet and increased physical activity, rather than as a stand-alone solution.
Novo Nordisk and the Wegovy boom
For retail investors, Wegovy is central to Novo Nordisk's growth story and global obesity strategy.
Clinical data and weight loss effect
In the pivotal STEP 1 trial, adults with obesity but without diabetes receiving Wegovy 2.4 mg once weekly lost on average around 15% of their body weight over 68 weeks, compared with about 2.4% in the placebo group, both on top of lifestyle intervention. More than half of participants on Wegovy achieved at least 15% weight loss, and nearly one-third reached 20% or more. These results pushed obesity treatment into a new dimension and ignited broad debate in medicine and society.
Beyond weight loss, trial participants saw improvements in markers such as blood pressure, waist circumference and lipid profile, underscoring that Wegovy addresses cardiovascular risk factors alongside weight. Novo Nordisk is running additional studies to examine long-term outcomes, including cardiovascular events and sustained weight management, with results expected to influence how guidelines frame GLP-1 therapies in obesity.
Safety profile and side effects
Common side effects of Wegovy include nausea, diarrhoea, vomiting, constipation and abdominal pain, particularly during the dose-escalation period. Most are mild to moderate and tend to decrease over time as the body adjusts, which is why doctors such as obesity specialist Dr. Mette Søndergaard insist on slow titration and patient counselling.
There are important warnings: Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma or in those with multiple endocrine neoplasia syndrome type 2, due to findings of thyroid C-cell tumours in rodent studies. The label also cautions about pancreatitis, gallbladder disease and, in some cases, worsening diabetic retinopathy, echoing the broader GLP-1 class profile.
Obesity market dynamics
Wegovy entered a global obesity market that has long been dominated by lifestyle advice and modest oral medications. Demand surged quickly in the US and parts of Europe, with pharmacies reporting waiting lists and insurers negotiating coverage criteria. In Denmark, the home base of Novo Nordisk, doctors describe a steady stream of patients asking explicitly for semaglutide by brand name, having read about Wegovy in the media.
This high demand has led to intermittent supply constraints, especially for starter doses, forcing Novo Nordisk to adjust launch plans and prioritise certain markets. The company has expanded production capacity for GLP-1 products, including a new facility in Novo Nordisk's network, to stabilise availability over the next few years.
Pricing and reimbursement
Wegovy is a prescription-only medicine, and its price varies significantly by market and payer. In the US, list prices run in the hundreds of dollars per month, but many patients access Wegovy through commercial insurance, Medicare or employer programmes, which may require specific BMI thresholds and documentation of previous weight-loss attempts. In European countries, national health systems and private insurers often tie reimbursement to strict criteria and sometimes limit duration.
For Novo Nordisk, pricing sits at the intersection of medical need and political debate. Obesity advocates argue that semaglutide should be treated like other chronic disease therapies, while budget-conscious policymakers worry about long-term cost if millions of patients take Wegovy for years. Novo Nordisk CEO Lars Fruergaard Jørgensen regularly faces these questions on earnings calls and at health policy events, explaining how the company balances access, investment and shareholder expectations.
Competition and pipeline
Wegovy competes directly with Eli Lilly's once-weekly tirzepatide, marketed for obesity as Zepbound in the US, and indirectly with older weight-loss medicines and bariatric surgery options. These competitors raise the bar on efficacy, with some tirzepatide data showing even higher weight loss, but Wegovy enjoys first-mover status and deep clinical experience.
Novo Nordisk is not standing still. The company is advancing oral semaglutide formulations and next-generation obesity candidates such as amycretin, aiming for stronger weight loss, easier administration and possibly different safety profiles. For investors, Wegovy is both a cash generator and a bridge to future obesity therapies that could extend Novo Nordisk's lead in the segment.
Doctor and patient experience
In a Copenhagen clinic, endocrinologist Dr. Søndergaard describes how she walks patients through the Wegovy pen, letting them hold the smooth plastic body and feel the click of the dose button before the first injection. The tactile experience matters: patients want to know they can handle the device at home without fear.
Many patients start Wegovy with a mix of hope and caution, having seen friends lose weight and then struggle to maintain it. Clinical guidance stresses that Wegovy is a chronic treatment; if patients stop, weight tends to return. Doctors work to anchor expectations, explaining that lifestyle changes remain essential even when appetite is dampened. Novo Nordisk supports this with patient materials and digital tools for tracking injections and weight over time.
Regulatory updates and labelling
Regulators continue to refine Wegovy labelling as new safety and efficacy data arise. The EMA and FDA monitor post-marketing reports, including rare adverse events, and can adjust warnings or usage guidance as needed. Novo Nordisk submits periodic safety updates and risk management plans, a standard requirement for novel therapies with large patient populations.
Some countries have taken steps to limit off-label use, for instance discouraging Wegovy prescriptions purely for cosmetic weight loss in people with normal BMI. This reflects a growing public discussion around fair access, where severely obese patients struggle to get coverage while some lower-risk consumers see Wegovy as a quick fix.
Impact on Novo Nordisk stock
For Novo Nordisk, Wegovy sits at the centre of a broader obesity-portfolio strategy that also includes lower-dose semaglutide for diabetes (Ozempic) and various insulin products. Together, these medicines drive revenue growth, reshape the company's risk profile and attract global investor interest. The Novo Nordisk A/S stock trades on Nasdaq Copenhagen in Danish kroner, with Wegovy seen as a major long-term growth engine for the share.
Key facts on Wegovy
- Product: Wegovy (semaglutide 2.4 mg)
- Manufacturer: Novo Nordisk A/S
- Category: Classic / Longseller obesity treatment
- Market launch: First approved in the US in 2021, EU in 2022
- MSRP / Price: Varies by market and payer; US list price in the hundreds of dollars per month
- Availability: Prescription-only, with intermittent supply constraints in some markets
- Target group: Adults with obesity or overweight and at least one weight-related condition
- Highlight / USP: Once-weekly GLP-1 injection with robust, trial-proven weight loss
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
